1532533-78-0

1532533-78-0 structure

Name: TGR-1202 hydrochloride
Chemical Name: TGR-1202 hydrochloride
CAS Number: 1532533-78-0
Molecular Formula: C₃₁H₂₅ClF₃N₅O₃
Molecular Weight: 608.010
Catalog: Research Areas Cancer
Create Date: 2018-03-29 20:48:37
Modify Date: 2024-01-07 17:40:00
Umbralisib hydrochloride (TGR-1202 hydrochloride) is a novel PI3Kδ inhibitor, with IC50 and EC50 of 22.2 nM and 24.3 nM, respectively; Umbralisib hydrochloride (TGR-1202 hydrochloride) is also active against CK1ε, with an EC50 value of 6.0 μM.

Name	TGR-1202 hydrochloride
Synonyms	2-{(1S)-1-[4-Amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]ethyl}-6-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one hydrochloride (1:1) 4H-1-Benzopyran-4-one, 2-[(1S)-1-[4-amino-3-[3-fluoro-4-(1-methylethoxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)-, hydrochloride (1:1)

Description	Umbralisib hydrochloride (TGR-1202 hydrochloride) is a novel PI3Kδ inhibitor, with IC50 and EC50 of 22.2 nM and 24.3 nM, respectively; Umbralisib hydrochloride (TGR-1202 hydrochloride) is also active against CK1ε, with an EC50 value of 6.0 μM.
Related Catalog	Research Areas >> Cancer
Target	PI3Kδ:22.2 nM (IC50)
In Vitro	Umbralisib (RP5264) causes a half-maximal inhibition of human whole blood CD19 cell proliferation between 100-300 nM[1]. In human lymphoma and leukemia cell lines, Umbralisib (TGR-1202; 10 nM-100 μM) inhibits phosphorylated AKT at Ser473 in a concentration-dependent manner. Umbralisib and carfilzomib synergistically kill blood cancer cells through disrupting the 4E-BP1-eIF4F-c-Myc axis. Umbralisib and carfilzomib in combination synergistically and selectively silence the c-Myc and E2F transcription programs. Umbralisib (15-50 μM) potently represses the expression of c-Myc in the DLBCL cell line LY7, and is uniquely characterized with structural features suitable for targeting CK1ε in lymphoma cells[2].
In Vivo	In a subcutaneous xenograft model of T-cell acute lymphoblastic leukemia (T-ALL) in NOD/SCID mice using the MOLT-4 cell line, Umbralisib (TGR-1202; 150 mg/kg, daily p.o.) significantly shrinks the tumors by day 25[2].
References	[1]. Swaroop Vakkalankaa, et al. Inhibition of PI3Kδ kinase by a selective, small molecule inhibitor suppresses B-cell proliferation and leukemic cell growth. [2]. Deng C, et al. Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies. Blood. 2017 Jan 5;129(1):88-99

Molecular Formula	C₃₁H₂₅ClF₃N₅O₃
Molecular Weight	608.010
Exact Mass	607.159790

1532533-78-0	1532533-67-7
1532533-72-4	1532533-75-7
1532533-69-9	894783-71-2
1048649-80-4	36362-09-1
160901-63-3	61535-49-7
1158522-08-7	940364-43-2
134104-43-1	98136-44-8
131615-57-1	6906-52-1
2098039-01-9	930439-75-1
1018584-77-4	1375289-11-4